ANGO - AngioDynamics Non-GAAP EPS of -$0.03 misses by $0.02 revenue of $80.7M misses by $2.49M

2023-03-30 07:12:51 ET

• AngioDynamics press release ( NASDAQ: ANGO ): Q3 Non-GAAP EPS of -$0.03 misses by $0.02 .
• Revenue of $80.7M (+9.1% Y/Y) misses by $2.49M .
• Fiscal 2023 Guidance: As a result of lower than anticipated AngioVac sales, management now expects the Company’s fiscal year 2023 net sales to be in the range of $338 million to $342 million, a decrease from its prior guidance of $342 million to $348 million vs consensus of $342.47M. Management now expects gross margin to be approximately 51.0% to 52.0%, a decrease from its prior guidance of 52.5% to 54.5%, and adjusted earnings per share to be in the range of a loss of $0.06 to a loss of $0.01, a decrease from its prior guidance of earnings of $0.01 to $0.06 vs consensus of $0.01. The adjusted earnings per share guidance is the result of higher than previously anticipated inflationary pressure combined with the lower AngioVac revenue.

For further details see: